ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $930,272 | -3.7% | 9,935 | -8.2% | 0.00% | – |
| Q2 2023 | $965,556 | -16.1% | 10,819 | +0.8% | 0.00% | – |
| Q1 2023 | $1,150,745 | -12.4% | 10,732 | -0.3% | 0.00% | – |
| Q4 2022 | $1,314,118 | +37.7% | 10,760 | +16.3% | 0.00% | – |
| Q3 2022 | $954,000 | +6.6% | 9,248 | -3.9% | 0.00% | – |
| Q2 2022 | $895,000 | -87.7% | 9,621 | -84.5% | 0.00% | -100.0% |
| Q1 2022 | $7,264,000 | -6.2% | 61,902 | +7.5% | 0.00% | 0.0% |
| Q4 2021 | $7,748,000 | -86.0% | 57,596 | -83.4% | 0.00% | -83.3% |
| Q3 2021 | $55,156,000 | +3621.7% | 346,041 | +2973.5% | 0.01% | – |
| Q2 2021 | $1,482,000 | +40.6% | 11,259 | +37.7% | 0.00% | – |
| Q1 2021 | $1,054,000 | +88.6% | 8,177 | +143.8% | 0.00% | – |
| Q4 2020 | $559,000 | +24.5% | 3,354 | +15.3% | 0.00% | – |
| Q3 2020 | $449,000 | -23.2% | 2,909 | -26.5% | 0.00% | – |
| Q2 2020 | $585,000 | -13.6% | 3,959 | -34.1% | 0.00% | – |
| Q1 2020 | $677,000 | +113.6% | 6,009 | +163.6% | 0.00% | – |
| Q4 2019 | $317,000 | -15.2% | 2,280 | -41.3% | 0.00% | – |
| Q3 2019 | $374,000 | -84.8% | 3,886 | -81.8% | 0.00% | -100.0% |
| Q2 2019 | $2,456,000 | -19.5% | 21,330 | -17.7% | 0.00% | 0.0% |
| Q1 2019 | $3,050,000 | +436.0% | 25,917 | +185.4% | 0.00% | – |
| Q4 2018 | $569,000 | -77.1% | 9,081 | -74.1% | 0.00% | -100.0% |
| Q3 2018 | $2,487,000 | +33.8% | 35,096 | +25.6% | 0.00% | 0.0% |
| Q2 2018 | $1,859,000 | +10.8% | 27,942 | +8.9% | 0.00% | – |
| Q1 2018 | $1,678,000 | -1.6% | 25,656 | -39.7% | 0.00% | – |
| Q4 2017 | $1,705,000 | +56.4% | 42,556 | +41.5% | 0.00% | – |
| Q3 2017 | $1,090,000 | +1059.6% | 30,076 | +788.8% | 0.00% | – |
| Q2 2017 | $94,000 | -34.3% | 3,384 | -33.6% | 0.00% | – |
| Q1 2017 | $143,000 | +34.9% | 5,100 | -2.8% | 0.00% | – |
| Q4 2016 | $106,000 | +17.8% | 5,247 | +1.9% | 0.00% | – |
| Q1 2015 | $90,000 | – | 5,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |